疫苗和免疫疗法
Our ambition is to develop and deliver transformative vaccines and antibodies, 为数百万人提供长期免疫, 哪里的疾病负担最重.
Home / 推荐全球最大网赌正规平台的治疗领域 /疫苗和免疫疗法
推荐全球最大网赌正规平台的承诺
We are committed to developing and delivering transformative vaccines and antibodies, 为数百万人提供长期免疫, 哪里的疾病负担最重. 在COVID-19大流行期间, we played an important role as part of a truly global effort to respond to a new and unprecedented challenge.1 We will continue to advance science in vaccines and immune therapies and work with partners to drive improvements in public health and ensure our science reaches millions more people.
推荐全球最大网赌正规平台的重点领域
实现推荐全球最大网赌正规平台的抱负, we are optimising the potential of both vaccines and antibodies to ensure no patient is left behind. We are engineering next generation vaccines that have the potential to generate potent and long-lasting immune responses. 同时, 推荐全球最大网赌正规平台正在开拓新的方法来开发高度针对性的, 长效抗体, 优化了推荐全球最大网赌正规平台的半衰期延长技术.2 推荐全球最大网赌正规平台专注于一系列病原体，包括SARS-CoV-2，3 influenza4 and RSV.5
互补的方法
Vaccines for active immunisation; antibodies for passive immunisation for those who can’t mount an immune response
技术
Innovative next-generation technologies for vaccines; accelerated human antibody discovery, long acting, 抗体的高产量生产.
Pathogens
sars - cov -2，流感，RSV & beyond
Our people
推荐全球最大网赌正规平台是一个充满激情和奉献精神的科学家团队, researchers, clinicians, 医疗和商业专业人士. 推荐全球最大网赌正规平台的发现正在打破新的界限, 推荐全球最大网赌正规平台的传统支持, 通过推荐全球最大网赌正规平台与商业伙伴的合作, 世界各地的学术和政府领导人.
The 疫苗和免疫疗法 unit is at the forefront of a new and exciting era of disease prevention. I am inspired by our team’s dedication to pushing the boundaries of science, 帮助为所有人创造一个更公平、更健康的未来.
Join us
Join and help us develop the next generation of vaccines and highly targeted, 长效抗体.
推荐全球最大网赌正规平台的药品
We cannot provide detailed information about our prescription medicines on this website, 遵守规定. 推荐全球最大网赌正规平台的药品 are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. 在某些情况下, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, 有时是任何, information on our prescription medicines so you should seek alternative trustworthy sources. 一定要向医疗保健专业人员咨询有关药物的建议.
Evusheld
替沙吉维单抗和西加维单抗
Fluenz Tetra/ fluumist Quadrivalent
活流感疫苗，鼻内注射
Synagis
palivizumab
V的管道&I
推荐全球最大网赌正规平台热衷于推动科学的发展, developing next generation vaccines and antibodies that have the power to transform the way we prevent and treat endemic and pandemic viruses.
Vaccine & 免疫疗法(截至2023年7月28日)
Phase I
Phase I
Phase II
Phase II
Phase III
模块项目
模块项目
Latest news
References
1. AstraZeneca. Vaxzevria shown in expert review to provide equally effective protection against COVID-19 hospitalisation and death as mRNA vaccines [Last accessed: October 2022]. 可从:http://www获得.um1515.net/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html.
2. 全球十大赌博靠谱平台新闻发布. COVID-19 Long-Acting AntiBody (LAAB) Combination AZD7442 Rapidly Advances into Phase III Clinical Trials.:最后访问时间:2022年10月. 可从:http://www获得.um1515.net/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html.
3. Voysey M et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397(10277):881–91.
4. 临床试验.gov. Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries (EVOLVE):最后访问时间:2022年10月. 可从:http://clinicaltrials获得.gov / ct2 /显示/ NCT05315323.
5. 临床试验.gov. A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants (MELODY) [Last accessed: October 2022]. 可从:http://clinicaltrials获得.gov / ct2 /显示/ NCT03979313
Veeva ID: Z4-49108
筹备日期:2022年10月